The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting

Clinical Cancer Research

Volumn 15, Issue 21, 2009, Pages 6495-6502

  Lunghi, Paolo ^a   Costanzo, Antonio ^c   Mazzera, Laura ^a   Rizzoli, Vittorio ^b   Levrero, Massimo ^d,e   Bonati, Antonio ^a,b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Rome Oncogenomic Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 37AA; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; ISOPROTEIN; MUTANT PROTEIN; NUTLIN 3; PACLITAXEL; PEPTIDE DERIVATIVE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN P53; PROTEIN P63; PROTEIN P73; RAPAMYCIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; MOLECULAR EVOLUTION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSACTIVATION;

APOPTOSIS; DNA-BINDING PROTEINS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 70350707752     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1229     Document Type: Review

References (91)

1. Lane DP, Crawford LV. Tantigen is bound to a host protein in SV40-transformed cells. Nature 1978;278:261-263
2. Linzer DI, Levine AJ. Characterization of a 54K dalton SV40 tumor antigen present in SV40- transformed cells and uninfected embryonal carcinoma cells. Cell 1979;17:43-52. (Pubitemid 9188209)
3. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-819 (Pubitemid 27357971)
4. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-316
5. Augustin M, Bamberger C, Paul D, Schmale H. Cloning and chromosomal mapping of the human p53-related KETgene to chromosome 3q27 and its murine homolog Ket to mouse chromosome 16. Mamm Genome 1998;9:899-902. (Pubitemid 28507203)
6. Osada M, Ohba M, Kawahara C, et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998;4:839-843 (Pubitemid 28331028)
7. Senoo M, Seki N, Ohira M, et al. A second p53- related protein, p73L, with high homology to p73. Biochem Biophys Res Commun 1998;248:603-607 (Pubitemid 28404468)
8. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 2002;18:90-95
9. Yang A, Walker N, Bronson R, et al. p73-deficient mouse have neurological pheromonal and inflammatory defects but lack spontaneous tumors. Nature 2000;404:99-103.
10. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 2000;289:304-306
11. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005;19:2122-2137
12. Grob TJ, Novak U, Maisse C, et al. Human ÄNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001;8:1213-1223 (Pubitemid 34048476)
13. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of ÄNp73: a newly identified isoform of human p73. Cancer Res 2002;62:636-641 (Pubitemid 34126932)
14. Fillippocich I, Sorokina N, Gatei M, et al. Transactivation- deficient p73 á (p73Äexon2) inhibits apoptosis and competes with p53. Oncogene 2001;20:514-522
15. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 2007;7:165-168
16. De Laurenzi V, Costanzo A, Barcaroli D, et al. Two new p73 splice variants, ã and ä, with different transcriptional activity. J Exp Med 1998;88:1763-1768 (Pubitemid 28516121)
17. De Laurenzi V, Catani MV, Terrinoni A, et al. Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants å and æ. Cell Death Differ 1999;6:389-390 (Pubitemid 29245951)
18. Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppression functions for the p53 family. Cancer Cell 2005;7:363-373 (Pubitemid 40544653)
19. Carroll DK, Carroll JS, Leong CO, et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 2006;8:551-561 (Pubitemid 43827347)
20. Beitzinger M, Hofmann L, Oswald C, et al. p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO J 2008;27:792-803.
21. Tomasini R, Tsuchihara K, Wilhelm M, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008;22:2677-2691
22. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG, Jr. Chemosensitivity linked to p73 function. Cancer Cell 2003;3:403-410
23. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003;3:387-402.
24. Concin N, Hofstetter G, Berger A, et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-73 cross-talk in vivo. Clin Cancer Res 2005;11:8372-8383
25. Zaika A, Slade N, Erster SH, et al. ÄNp73, a dominant negative inhibitor of wild type p53 and TAp73, is upregulated in human tumors. J Exp Med 2002;196:765-780
26. Concin N, Becker K, Slade N, et al. TransdominantÄTAp73 isoformsare frequently up-regulated in ovarian cancer, evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004;64:2449-2460
27. Cam H, Griesmann H, Beitzinger M, et al. p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 2006;10:281-293
28. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006;9:45-56. (Pubitemid 43069510)
29. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007;117:1370-1380 (Pubitemid 46718425)
30. Frasca F, Vella V, Aloisi A, et al. p73 tumorsuppressor activity is impaired in human thyroid cancer. Cancer Res 2003;63:5829-5837 (Pubitemid 37187481)
31. Muller M, Schilling T, Sayan AE, et al. TAp73/ÄNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005;12:1564-1577
32. Casciano I, Mazzocco K, Boni L, et al. Expression of ÄNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002;9:246-251
33. Wager M, Guilhot J, Blanc JL, et al. Prognostic value of increase in transcript levels of Tp73 ÄEx2-3 isoforms in low-grade glioma patients. Br J Cancer 2006;95:1062-1069 (Pubitemid 44608169)
34. Becker K, Pancoska P, Concin N, et al. Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers. Int J Oncol 2006;29:889-902.
35. Lunghi P, Costanzo A, Levrero M, Bonati A. Treatment with arsenic trioxide (ATO) and MEK1 inhibition activates the p73-53AIP1 apoptotic pathway in leukemia cells. Blood 2004;104:519-525 (Pubitemid 38900036)
36. Lunghi P, Costanzo A, Salvatore L, et al. MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood 2006;107:4549-4553 (Pubitemid 43801384)
37. Rizzo MG, Giombini E, Diverio D, et al. Analysis of p73 expression pattern in acute myeloid leukemias: lack of ÄN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia 2004;18:1804-1809 (Pubitemid 39530009)
38. Mainardi S, Pelosi A, Palescandolo E, et al. ÄNp73 is a transcriptional target of the PML/ RARá oncogene in myeloid differentiation. Cell Death Differ 2007;14:1968-1971
39. Dominguez G, Garcia JM, Pena C, et al. ÄTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 2006;24:1-11.
40. Bozzetti C, Nizzoli R, Musolino M, et al. p73 and p53 pathway in human breast cancers. J Clin Oncol 2007;25:1541-1543
41. Di Vinci A, Sessa F, Casciano I, et al. Different intracellular compartmentalization of TA and ÄNp73 in non-small cell lung cancer. Int J Oncol 2009;34:449-456
42. Uramoto H, Sugio K, Oyama T, et al. Expression of äNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 2004;10:6905-6911 (Pubitemid 39383040)
43. Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999;399:806-809 (Pubitemid 29293179)
44. Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73á and their collaboration to induce apoptosis. Nature 1999;399:809-813 (Pubitemid 29293180)
45. Yuan Z-M, Shioya H, Ishiko T, et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999;399:814-817 (Pubitemid 29293181)
46. Tsai KK, Yuan ZM. c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer Res 2003;63:3418-3424
47. Sanchez-Prieto R, Sanchez-Arevalo VJ, Servitja JM, Gutkind JS. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene 2002;21:974-979 (Pubitemid 34146311)
48. Vella V, Zhu J, Frasca F, et al. Exclusion of c- Abl from the nucleus restrains the p73 tumor suppression function. J Biol Chem 2003;278:25151-25157 (Pubitemid 37548679)
49. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001;7:228-234 (Pubitemid 32148491)
50. Costanzo A, Merlo P, Pediconi N, et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 2002;9:175-186
51. Mantovani F, Piazza S, Gostissa M, et al. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol Cell 2004;14:625-636 (Pubitemid 38739084)
52. Strano S, Monti O, Pediconi N, et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol Cell 2005;18:447-459
53. Levy D, Adamovich Y, Reuven N, Shaul Y. Yap1 phosphorylation by c-Abl is a critical step in selective activation of pro-apoptotic genes in response to DNA damage. Mol Cell 2008;29:350-361 (Pubitemid 351215937)
54. Jiménez-Velasco A, Roman-Gomez J, Agirre X, et al. Down-regulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia 2005;19:2347-2350 (Pubitemid 41741637)
55. Takahashi Y, Miyoshi Y, Takahata C, et al. Downregulation of LATS1 and LATS2mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005;11:1380-1385 (Pubitemid 40315216)
56. Kawahara M, Hori T, Chonabayashi K, Oka T, Sudol M, Uchiyama T. Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73. Blood 2008;112:3856-3866
57. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851-859 (Pubitemid 32880294)
58. Lee JT, McCubrey JA. The Raf/MEK/ERK (MAPK) signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 2002;16:486-507.
59. Lunghi P, Tabilio A, Dall'Aglio PP, et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia 2003;17:1783-1793 (Pubitemid 37185254)
60. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000;102:849-862
61. Matsuda K, Yoshida K, Taya Y, Nakamura Y, Arakawa H. p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res 2002;62:2883-2889 (Pubitemid 34525775)
62. Lunghi P, Giuliani N, Mazzera L, et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 2008;112:2450-2462
63. Shammas MA, Neri P, Koley H, et al. Specific killing of multiple myeloma cells by (-)-epigallocatechin- 3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 2006;108:2804-2810
64. Raab MS, Breitkreutz I, Tonon G, et al. Targeting PKC: a novel role for â catenin in ER stress and apoptosis signalling. Blood 2009;12:1513-1521
65. Bernassola F, Salomoni P, Oberst A, et al. Ubiquitin-dependent degradation of p73 is inhibited by PML. J Exp Med 2004;199:1545-1547 (Pubitemid 38780409)
66. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008;453:1072-1078 (Pubitemid 351871736)
67. Lapi E, Di Agostino S, Donzelli S, et al. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell 2008;32:803-814
68. Hermeking H. p53 enters the microRNA world. Cancer Cell 2007;12:414-418
69. SampathD,CalinGA, PuduvalliVK, et al.Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 2009;113:3744-3753
70. Benard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat 2003;21:182-191 (Pubitemid 36292961)
71. Bell HS, Dufes C, O'Prey J, et al. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest 2007;117:1008-1018 (Pubitemid 46556757)
72. BergamaschiD, SamuelsY,JinB,Duraisingham S, Crook T, Lu X. ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol 2004;24:1341-1350 (Pubitemid 38112194)
73. Bergamaschi D, Samuels Y, Sullivan A, et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 2006;38:1133-1141
74. Mantovani F, Tocco F, Girardini J, et al. The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASSP. Nat Struct Mol Biol 2007;14:912-920
75. Wang W, Kim S-H, El-Deiry WS. Smallmolecule modulators of p53 family signaling andantitumor effects inp53-deficienthuman colon tumor xenografts. Proc Natl Acad Sci U S A 2006;103:1103-1108 (Pubitemid 44148408)
76. Kravchenko JE, Ilyinskaya GV, Komarov PG, et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73- dependent salvage pathway. Proc Natl Acad Sci U S A 2008;105:6302-6307
77. Di Agostino S, Cortese G, Monti O, et al. The disruption of the protein complex mutantp53/ p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle 2008;7:3440-3447
78. Irwin MS. Family feud in chemosensitivity. P73 and mutant p53. Cell Cycle 2004;3:319-323
79. Bell HS, Ryan KM. iASPP inhibition: increased options in targeting the p53 family for cancer therapy. Cancer Res 2008;68:4959-4962
80. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8:129-138
81. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M.Mdm2inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription- dependent and transcription independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006;108:993-1000. (Pubitemid 44154636)
82. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005;106:3150-3159
83. Lau LMS, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-2 binding and enhances p73 function. Oncogene 2008;27:997-1003. (Pubitemid 351225385)
84. Dar AA, Belkhiri A, Ecsedy J, Zaika A, El-Rifai W. Aurora kinase A inhibition leads to p73- dependent apoptosis in p53-deficient cancer cells. Cancer Res 2008;68:8998-9004.
85. Lau LMS, Wolter JK, Lau JTML, et al. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 2009;28:2024-2033
86. Meric-Berstein F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009;27:2278-2287
87. Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA. A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol 2008;28:5951-5964
88. Crighton D, O'Prey J, Bell HS, Ryan KM. p73 regulates DRAM-independent autophagy that does not contribute to programmed cell death. Cell Death Differ 2007;14:1071-1079 (Pubitemid 46785098)
89. Rosenbluth JM, Pietenpol JA. mTOR regulates autophagy-associated genes downstream of p73. Autophagy 2009;5:114-116
90. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-1935
91. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007;7:54-60. (Pubitemid 46020847)